All the Active Ingredient Drugs
Monoclonal Antibody. Ustekinumab 45 mg / 0.5 ml, 90 mg/ml. PRE-FILLED SYR. (SOL. FOR INJECT.): 1 x 0.5 ml, 1 x 1 ml. Dosage must be ajust. individ. according to indication and its severity.
Plaque psoriasis: Tmt. of moder. to severe plaque psoriasis in adult pts. (18 yrs. or older) who have failed to, have a C/I to, or who are intolerant to other system. Psoralen plus U.V (PUVA).
Ped. Plaque Psoriasis: Tmt. of moder- severe plaque psoriasis in adolesc. pts. from the age of 12 yrs. and older, who are inadeq. control. by, or are intoler. to other system. therapies or phototherapies.
Psoriatic arthritis (PsA): Alone or in comb. with MTX, is indic. for the tmt. of active psoriatic arthritis in adult pts. when the response to previous non-biolog. dis.-modif. anti-rheumatic drug (DMARD) therapy has been inadequate.
Crohn’s Dis.: Tmt. of adult pts. with moderat. – sev. active Crohn’s dis. who have had an inadeq. response with, lost response to, or were intolerant to either convent. therapy or a TNFα antag. or have medical contraindic. to such therapies.
C/I: Hypersens. Clinically import. act. infect.
Human Monoclonal Antibody. Ustekinumab 130 mg / 26 ml. Vial: conc. for sol. for IV inj. 1X 130 mg/26 ml
Dose to be indiv. adj. as per ptt. weight.
For adlt. pts. with mod. to sev. active Crohn’s dis. who have had an inadeq. resp. with, lost resp. to, or were intoler. to either convent. ther. or a TNFα antag. or have contraindic. to such ther.
Also for adlt. pts. with mod. to sev. act. UC who have had an inadeq. resp. with, lost resp. to, or were intoler. to either convent. ther. or a boil. or have contraindic. to such ther.
C/I: Hypersens. Import., act. infect.
Monoclonal Antibody. Ustekinumab 45 mg / 0.5 ml. VIAL (SOL. FOR INJECT.): 1 x 0.5 ml. Dosage must be ajust. individ. according to indication and its severity.
Plaque psoriasis: Tmt. of moder. to severe plaque psoriasis in adult pts. (18 yrs. or older) who have failed to, have a C/I to, or who are intolerant to other system. Psoralen plus U.V (PUVA).
Ped. Plaque Psoriasis: Tmt. of moder- severe plaque psoriasis in adolesc. pts. from the age of 12 yrs. and older, who are inadeq. control. by, or are intoler. to other system. therapies or phototherapies.
Psoriatic arthritis (PsA): Alone or in comb. with MTX, is indic. for the tmt. of active psoriatic arthritis in adult pts. when the response to previous non-biolog. dis.-modif. anti-rheumatic drug (DMARD) therapy has been inadequate.
Crohn’s Dis.: Tmt. of adult pts. with moderat. – sev. active Crohn’s dis. who have had an inadeq. response with, lost response to, or were intolerant to either convent. therapy or a TNFα antag. or have medical contraindic. to such therapies.
C/I: Hypersens. Clinically import. act. infect.
Interleukin Inhibitor. Ustekinumab 45 mg, 90 mg, 130 mg. PF syr: 1X 45/90 mg
VIAL: Sol. for SC inj.: 45 mg
VIAL: Concentr. for sol. for infus. :130 mg for IBD indicat. only
Init. dose of 45 mg SC, followed by 45 mg 4 weeks later, and then every 12 weeks. Discont. if no improvem. after 28 weeks. Ped. pop and IBD: See lit.
Plaque psor.: for moder. to sev. plaque psoriasis in adlts.(18 years or older) who failed to respond to, or who have a contraindic. to, or are intol. to other syst. ther. incl. ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A). Ped. plaque psoriasis: moder. to sev. plaque psoriasis in pts. from age of 6 years and older, who are inadeq. ctrolled by, or are intol. to, other syst. ther. or phototherapies. Psoriatic arthritis (PsA) alone or in combination with MTX: for tmt. of act. psoriatic arthritis in adlts when the resp. to prev. non-biological DMARD has been inadeq. Crohn’s Disease: adlts. with moder. to sev. act. Crohn’s dis. who had an inadeq. resp. with, lost resp. to, or were intol. to either convent. ther. or a TNFα antagonist or have contraindic. to such ther. Ulcerative colitis: adlts. with moder. to sev. act. UC who had an inadeq. resp. with, lost resp. to, or were intol. to either convent. ther. or a biologic or have contraindic. to such ther.
C/I: Hypersens. Clinic. important, act. infection.
